AVGO
Broadcom
-- 224.800 NVDA
NVIDIA
-- 134.250 TSLA
Tesla
-- 436.230 AMD
Advanced Micro Devices
-- 126.910 PLTR
Palantir
-- 76.070 
NEWS
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
Esperion Therapeutics (NASDAQ: ESPR) has entered into a licensing agreement with Neopharm Israel for exclusive commercialization rights of NEXLETOL® and NEXLIZET® in Israel. The agreement includes an upfront payment, near-term milestone payments, and tiered royalties on product sales.
Under the agreement terms, Neopharm will receive exclusive commercialization rights in Israel, Gaza, and West Bank. Esperion will receive a one-time upfront cash payment within 30 days of signing, plus an additional payment following marketing approval and inclusion in the National Healthcare Reimbursement Basket. The partnership aims to address cardiovascular disease, which remains a leading cause of death globally.
Under the agreement terms, Neopharm will receive exclusive commercialization rights in Israel, Gaza, and West Bank. Esperion will receive a one-time upfront cash payment within 30 days of signing, plus an additional payment following marketing approval and inclusion in the National Healthcare Reimbursement Basket. The partnership aims to address cardiovascular disease, which remains a leading cause of death globally.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment